Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)
What is the purpose of this trial?
The purpose of this study is to assess the safety, tolerability and biomarker efficacy of Gantenerumab and Solanezumab in individuals who have an autosomal dominant Alzheimer's disease (ADAD) mutation.
- Ages18 years - 80 years
- Trial withWashington University School of Medicine
- Start Date03/11/2014
- End Date09/30/2023
- Last Updated07/15/2021
- Study HIC#1308012526